Partner Therapeutics
Focus: Partner Therapeutics is a Massachusetts-based biologics company focused on oncology, neurology, infectious diseases, and respiratory indications. The company operates as a mid-stage biotech with a marketed infectious disease asset (ALINIA/nitazoxanide) and an early-stage pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
2 recent layoff filings (12 mo) — 122 affected
- 1/1/2026 — New Providence, NJ · 61 affected · Layoff
- 1/1/2026 — New Providence, NJ · 61 affected · Layoff
Source: state DOL filings via Big Local News
About Partner Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Partner Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
LOE Approaching
Core marketed NDA with multi-indication label expansion potential, but patent protection approaching expiry, creating near-term revenue cliff risk.
Help build intelligence for Partner Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.